ASTELLAS PHARMA UNSP.ADR Cash Flow-to-Debt Ratio
ASTELLAS PHARMA UNSP.ADR cash flow-to-debt ratio. ASTELLAS PHARMA UNSP.ADR (YPHA) has a Cash Flow-to-Debt Ratio of 0.11x as of March 2025, meaning its operating cash flow of €194.51 Billion could theoretically repay 0% of its total liabilities (€1.83 Trillion) in one year. Check YPHA cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of ASTELLAS PHARMA UNSP.ADR (2022–2025)
Cash flow-to-debt ratio of ASTELLAS PHARMA UNSP.ADR from 2022 to 2025. Historical debt coverage capacity for ASTELLAS PHARMA UNSP.ADR across 4 annual periods. Check ASTELLAS PHARMA UNSP.ADR (YPHA) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
ASTELLAS PHARMA UNSP.ADR Cash Flow-to-Debt Ratio by Year (2022–2025)
ASTELLAS PHARMA UNSP.ADR cash flow-to-debt ratio by year from 2022 to 2025. Year-by-year debt coverage analysis for ASTELLAS PHARMA UNSP.ADR. For the full cash flow conversion analysis, see YPHA cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.11x | €194.51 Billion | €1.83 Trillion | ▲ +21.9% |
| 2024 | 0.09x | €172.47 Billion | €1.97 Trillion | ▼ -74.7% |
| 2023 | 0.35x | €327.77 Billion | €948.56 Billion | ▲ +17.1% |
| 2022 | 0.30x | €257.44 Billion | €872.09 Billion | — |